German
Spanish
Hindi
Arabic
French
Chinese (Traditional)Pfizer (PFE) reported $17.76 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 24.7%. EPS of $0.63 for the same period compares to $0.10 a year ago.
The reported revenue represents a surprise of +1.52% over the Zacks Consensus Estimate of $17.5 billion. With the consensus EPS estimate being $0.48, the EPS surprise was +31.25%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
View all Key Company Metrics for Pfizer here>>>
Shares of Pfizer have returned -2.6% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research